Palliative care for adults: strong opioids for pain relief (CG140)
Pain is one of the most common and debilitating symptoms of progressive myeloma. This guidance written by NICE outlines safe use of opioids for adults with advanced disease.
Pain is one of the most common and debilitating symptoms of progressive myeloma. This guidance written by NICE outlines safe use of opioids for adults with advanced disease.
A Myeloma UK funded study, published recently in the European Journal of Haematology, has found that a large number of symptoms occur frequently in myeloma patients, highlighting the importance of routine assessments throughout the disease trajectory in order to achieve optimal quality of life for patients. Led by Christina Ramsenthaler and Prof Irene Higginson, Department of…
New investigational drugs with single-agent activity in multiple myeloma.
Rajan AM et al. Blood Cancer J. 2016 Jul 29;6(7):e451. doi: 10.1038/bcj.2016.53.
A revised Cancer Drugs Fund (CDF) together with wider changes in the way the National Institute for Health and Care Excellence (NICE) assesses cancer drugs has recently been launched. Developed through a partnership between National Health Service (NHS) England and NICE, the new CDF allows drugs which meet set criteria under a managed access agreement…
The International Myeloma Working Group (IMWG) has recently published further consensus criteria for defining disease response in myeloma. Since the original response criteria were set in 2006, newer, more sensitive methods can now quantify myeloma cells as low as 1 in a million. Published in the Lancet Oncology, the updated criteria identify responses beyond complete response…
A study published recently in Nature Communications has identified eight new genetic risk loci for myeloma, providing further insights into the genetic and biological basis of its predisposition. The research, performed at The Institute of Cancer Research (ICR) and part funded by Myeloma UK involved a meta-analysis of pooled data from several independent genome-wide association…
This NICE guidance covers medical and NHS service recommendations for children and adults who have received a diagnosis of a haematological cancer.
The National Institute of Health and Care Excellence (NICE) has set out new guidance for the diagnosis, treatment and care of myeloma patients with the aim of providing consistently excellent patient-focused care within NHS England. The new guidance has been created to cover aspects of management where in the past there was uncertainty or variation…